{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = [4-(5-Acetyloxy-1-ethyl-3-methylindol-2-yl)phenyl] acetate
| image = Zindoxifene.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 86111-26-4
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 65645
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 59082
| UNII = 1IRS95M8DN
| KEGG = C14745
| ChEBI = 35052
| ChEMBL = 32227

<!--Chemical data-->
| C=21 | H=21 | N=1 | O=4
| SMILES = CCN1C2=C(C=C(C=C2)OC(=O)C)C(=C1C3=CC=C(C=C3)OC(=O)C)C
| StdInChI_Ref = 
| StdInChI = 1S/C21H21NO4/c1-5-22-20-11-10-18(26-15(4)24)12-19(20)13(2)21(22)16-6-8-17(9-7-16)25-14(3)23/h6-12H,5H2,1-4H3
| StdInChIKey_Ref = 
| StdInChIKey = KSZGVNZSUJHOJA-UHFFFAOYSA-N
| synonyms = D-16726; NSC-341952
}}

'''Zindoxifene''' ([[International Nonproprietary Name|INN]]; former developmental code names '''D-16726''', '''NSC-341952''') is a [[nonsteroidal]] [[selective estrogen receptor modulator]] (SERM) that was under development in the 1980s and early 1990s for the treatment of [[breast cancer]] but was not marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1300|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=1300–}}</ref> It showed [[estrogen]]ic-like activity in [[preclinical research|preclinical studies]] and failed to demonstrate effectiveness as a treatment for breast cancer in [[clinical trial]]s.<ref name="MaximovMcDaniel2013">{{cite book|author1=Philipp Y. Maximov|author2=Russell E. McDaniel|author3=V. Craig Jordan|title=Tamoxifen: Pioneering Medicine in Breast Cancer|url=https://books.google.com/books?id=p-W5BAAAQBAJ&pg=PA170|date=23 July 2013|publisher=Springer Science & Business Media|isbn=978-3-0348-0664-0|pages=170–}}</ref><ref name="Elsevier2013">{{cite book|title=Hormones and Breast Cancer|url=https://books.google.com/books?id=vBvzF6HQ4-QC&pg=PA32|date=25 June 2013|publisher=Elsevier|isbn=978-0-12-416676-9|pages=32–}}</ref> Zindoxifene was the [[lead compound]] of the distinct [[2-phenylindole]] class of SERMs,<ref name="OettelSchillinger2012">{{cite book|author1=Michael Oettel|author2=Ekkehard Schillinger|title=Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens|url=https://books.google.com/books?id=0BfrCAAAQBAJ&pg=PA68|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-58616-3|pages=68–69}}</ref><ref name="DIANE">{{cite book|title=International position paper on women's health and menopause : a comprehensive approach|url=https://books.google.com/books?id=NCzYsz6Uv0IC&pg=PA111|publisher=DIANE Publishing|isbn=978-1-4289-0521-4|pages=111–}}</ref> and the marketed SERM [[bazedoxifene]] was derived from the major [[active metabolite]] of zindoxifene, [[D-15414]].<ref name="MaximovMcDaniel2013" /><ref name="Elsevier2013" /> Zindoxifene was first described in 1984.<ref name="Elks2014" />

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800000885 Zindoxifene - AdisInsight]


{{Estrogen receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:Acetate esters]]
[[Category:Hormonal antineoplastic drugs]]
[[Category:Indoles]]
[[Category:Selective estrogen receptor modulators]]


{{antineoplastic-drug-stub}}